PTGES3 is a Putative Prognostic Marker in Breast Cancer

Adekeye, Adeseye; Agarwal, Divyansh; Nayak, Anupma; Tchou, Julia

doi:10.1016/j.jss.2021.08.033

Cited by 11 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that elevated PTGES3 expression was observed at BRCA, leading to poor survival according to previous results ( 22 ). According to our study, significant differences in PTGES3 expression level were found with 14 types of cancer.…”

Section: Discussionsupporting

confidence: 59%

Comprehensive pan-cancer analysis of PTGES3 and its prognostic role in hepatocellular carcinoma

et al. 2023

View full text Add to dashboard Cite

IntroductionPTGES3, also known as p23, is a molecule chaperone of Hsp90 that is involved in the pathogenesis of malignant tumors. Increasing studies have shown that PTGES3 plays a nonnegligible role in tumor development. However, analysis of PTGES3 in pan-cancer has not been performed yet.MethodsWe explored the role of PTGES3 in 33 types of tumors and depicted the potentialimmune-related pathways among them. Using multiple databases includingTCGA, LinkedOmics, GDSC, and TIMER, we made a comprehensive analysis to explore whether there was an interaction between PTGES3 and prognosis, DNA methylation, copy number variation (CNV), tumor mutational burden (TMB), microsatellite instability (MSI), and tumor immune microenvironment (TME).ResultsOur study revealed that PTGES3 expression level was upregulated in most cancers. PTGES3 was also associated with a positive or negative prognosis in a variety of cancers, which was mainly associated with DNA methylation, CNV, MSI, TMB, andmismatch repair-related genes. High PTGES3 expression was related to the infiltration of Th2 subsets of CD4+ T cells and immune checkpoint-related genes in most cancers, especially in hepatocellular carcinoma (HCC). Enrichment analysis demonstrated that PTGES3 was involved in cellular processes including DNA replication and spliceosome. The relationship between PTGES3 expression and HCC progression was verified at the protein level through immune histochemical analysis.ConclusionsOur research demonstrated theprognostic predictive value of PTGES3 in a wide range of cancers, which was alsoassociated with the process of tumor immune infiltration. As a result, it suggestedthat PTGES3 was a valuable prognostic biomarker in HCC treatment.

show abstract

Section: Discussionsupporting

confidence: 59%

Comprehensive pan-cancer analysis of PTGES3 and its prognostic role in hepatocellular carcinoma

et al. 2023

View full text Add to dashboard Cite

show abstract

“…PAPOLA (Komini et al 2021) is observed to be associated with proliferation, which is an ideal candidate target from prior research as it is overexpressed by 119% in triple-negative breast tumors. Likewise, BIRC2 (Samanta et al 2020), NUSAP1 (De Luca, Romano, and Bucci 2021), ATP6V1G1 (Qiu et al 2021), PTGES3 (Adekeye et al 2022), that are overexpressed by 118%, 111%, 117%, and 118% respectively, are potential biomarkers in breast can-cer, have also been overexpressed in iCCA proliferation, giving the researchers an opportunity for drug re-purposing. CCNY (Liu et al 2016), and ZFP36L1 (Suk et al 2018) are potential biomarkers in Ovarian cancer and are also overexpressed by 127% and 123%, respectively.…”

Section: Results and Experimental Analysismentioning

confidence: 99%

GMRC: Gene Median Ratio Clustering Algorithm to Rank Clusters and Identify Driver Genes in Intrahepatic Cholangiocarcinoma

Puri

Arora

Tanwar

et al. 2022

Preprint

View full text Add to dashboard Cite

Intrahepatic Cholangiocarcinoma (iCCA) is an asymptomatic malignancy of the bile ducts in the liver. The research is predicated on the assumption that a disease is a cluster of genes interacting in a regulatory network and a few driver genes regulating the network. Keeping this in mind, the paper proposes a Gene Median Ratio Clustering (GMRC) algorithm to independently rank the clusters and identify driver genes by hybridizing gene-median ratio (GMR) and em gene cluster network GCN. GMR then employs the Poisson distribution to translate right-skewed data into the Normal distribution and the Anscombe transformation to eliminate data noise and determine the median difference in gene concentration between distinct disease stages. Additionally, hierarchical clustering is separately applied to raw data for gene clustering based on the RNA sequence count. In the process, GMRC is evaluated over the GSE32225 dataset of 155 patients to extract 12 clusters network for proliferation patients.

show abstract

“…From the perspective of inhibiting lung cancer invasion and metastasis, which provided a theoretical basis for clinical treatment of lung cancer as well as screening its metastatic potential agents. PTGES3 (p23), namely prostaglandin E synthase 3, is a molecular chaperone protein and a known potential oncogene [22][23][24] . Previous studies have shown that [23] p23 is highly expressed in lung adenocarcinoma, and the overexpression of p23 is related to the short overall survival and poor prognosis of lung cancer patients.…”

Section: Discussionmentioning

confidence: 99%

“…Prostaglandin E synthase 3 (p23) is a highly conserved protein encoded by PTGES3 gene [20,21] , which is often overexpressed in various cancers, including prostate cancer and breast cancer, as well as lung cancer [22][23][24][25][26][27] . The current understanding of p23 mainly focuses on its role as a co-partner of heat shock protein 90 (Hsp90) [28,29] , that can stabilize the complex formed by Hsp90 and its client proteins, including estrogen receptor [30] , androgen receptor [31] and telomerase [32] .…”

Section: Introductionmentioning

confidence: 99%

RBM14 enhances transcriptional activity of p23 regulating CXCL1 expression to induce EMT in lung cancer

Yu,

Zhang,

Peng

et al. 2024

Preprint

View full text Add to dashboard Cite

Metastasis serves as a malignant indicator and biological characteristic of pulmonary carcinoma. Epithelial-mesenchymal transition (EMT) plays a pivotal role in facilitating tumor invasion and metastasis, and enhances the aggressiveness of tumor cells. Prostaglandin E synthase 3 (PTGES3) functions as an HSP90 co-chaperone. Our previous study revealed its HSP90-independent role as a transcription factor involved in cancer-related inflammation. Our present study aims to investigate the impact and mechanism of p23 on lung cancer metastasis. By utilizing cell models in vitro and mouse tail vein metastasis modelsin vivo, our results provide solid evidences that p23 plays a crucial role in promoting lung cancer metastasis through regulating the downstream CXCL1 expression, which is not achieved independently, but rather through formatting a complex with RBM14, thereby facilitating the occurrence and progression of EMT in lung cancer. Therefore, our study demonstrates the potential therapeutic application of the RBM14-p23-CXCL1-EMT axis in targeting lung cancer metastasis.

show abstract

PTGES3 is a Putative Prognostic Marker in Breast Cancer

Cited by 11 publications

References 30 publications

Comprehensive pan-cancer analysis of PTGES3 and its prognostic role in hepatocellular carcinoma

Comprehensive pan-cancer analysis of PTGES3 and its prognostic role in hepatocellular carcinoma

GMRC: Gene Median Ratio Clustering Algorithm to Rank Clusters and Identify Driver Genes in Intrahepatic Cholangiocarcinoma

RBM14 enhances transcriptional activity of p23 regulating CXCL1 expression to induce EMT in lung cancer

Contact Info

Product

Resources

About